Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Plus AVD in Pediatric, Adolescent, And Young Adult Patients With Newly Diagnosed Early-stage Non-bulky Classical Hodgkin Lymphoma
NCT07551583Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2026
- Primary completion
- Dec 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in Hodgkin lymphoma (HL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events and Overall Response Rate. Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT07551583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07551583.